ID30327A - EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc - Google Patents

EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc

Info

Publication number
ID30327A
ID30327A IDW00200101488A ID20011488A ID30327A ID 30327 A ID30327 A ID 30327A ID W00200101488 A IDW00200101488 A ID W00200101488A ID 20011488 A ID20011488 A ID 20011488A ID 30327 A ID30327 A ID 30327A
Authority
ID
Indonesia
Prior art keywords
proteins
fotiin
export
fusion
expression
Prior art date
Application number
IDW00200101488A
Other languages
English (en)
Inventor
Lo Kin Ming
Zhang Jinyang
Stephen Gillies
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of ID30327A publication Critical patent/ID30327A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
IDW00200101488A 1999-01-07 2000-01-07 EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc ID30327A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11507999P 1999-01-07 1999-01-07

Publications (1)

Publication Number Publication Date
ID30327A true ID30327A (id) 2001-11-22

Family

ID=22359200

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101488A ID30327A (id) 1999-01-07 2000-01-07 EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc

Country Status (16)

Country Link
US (1) US20040053366A1 (id)
EP (1) EP1141013A2 (id)
JP (1) JP2002534962A (id)
KR (1) KR20020007287A (id)
CN (1) CN1341121A (id)
AU (1) AU778939B2 (id)
BR (1) BR0007414A (id)
CA (1) CA2356401A1 (id)
CZ (1) CZ20012406A3 (id)
HU (1) HUP0105090A2 (id)
ID (1) ID30327A (id)
MX (1) MXPA01006922A (id)
NO (1) NO20013371L (id)
SK (1) SK9432001A3 (id)
WO (1) WO2000040615A2 (id)
ZA (1) ZA200105352B (id)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
DE69931908T2 (de) * 1998-04-15 2007-01-11 Lexigen Pharmaceuticals Corp., Lexington Steigerung der antikörper-zytokin-fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1252192B1 (en) 2000-02-11 2006-08-16 MERCK PATENT GmbH Enhancing the circulating half-life of antibody-based fusion proteins
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
CN100404673C (zh) 2001-02-19 2008-07-23 默克专利有限公司 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途
BR0207267A (pt) * 2001-02-19 2004-02-10 Merck Patent Gmbh Proteìnas artificiais com imunogenicidade reduzida
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CA2510180C (en) * 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1699822B1 (en) 2003-12-30 2008-04-23 MERCK PATENT GmbH Il-7 fusion proteins with antibody portions, their preparation and their use
ES2387028T3 (es) * 2003-12-31 2012-09-12 Merck Patent Gmbh Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
PL1706428T3 (pl) 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101072793B (zh) * 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
ES2408704T3 (es) 2005-01-05 2013-06-21 Biogen Idec Ma Inc. Moléculas de unión a Cripto
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
EP1909823A2 (en) * 2005-07-29 2008-04-16 Amprotein Corporation Chimeric therapeutic agents
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1801121A1 (en) * 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
EA016429B1 (ru) 2005-12-30 2012-04-30 Мерк Патент Гмбх Антитела против cd19 с пониженной иммуногенностью
ATE555125T1 (de) * 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
US20080227669A1 (en) * 2007-03-12 2008-09-18 Halliburton Energy Services, Inc. Corrosion-inhibiting additives, treatment fluids, and associated methods
EP2326339A4 (en) 2008-05-21 2012-06-20 Neurotez Inc METHOD FOR TREATING PROGRESSIVE COGNITIVE DISORDER IN CONNECTION WITH NEUROFIBRILLARY TANGLES
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
WO2012138919A2 (en) 2011-04-08 2012-10-11 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
EP3683228A3 (en) 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
SG11201408530YA (en) * 2012-08-02 2015-03-30 Hoffmann La Roche Method for producing monomeric and multimeric molecules and uses thereof
DK2880170T3 (en) 2012-08-02 2016-10-24 Hoffmann La Roche PROCEDURE FOR PREPARING SOLUBLE FcR AS Fc FUSION WITH INERT IMMUNOGLOBULIN Fc REGION AND APPLICATIONS THEREOF
SG11201500682WA (en) * 2012-09-07 2015-02-27 Sanofi Sa Fusion proteins for treating a metabolic syndrome
LT3027642T (lt) 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA3014498A1 (en) 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN110267674A (zh) * 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
PE20201350A1 (es) 2018-04-09 2020-11-30 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO1996031526A1 (en) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound

Also Published As

Publication number Publication date
AU778939B2 (en) 2004-12-23
WO2000040615A2 (en) 2000-07-13
BR0007414A (pt) 2001-10-16
NO20013371D0 (no) 2001-07-06
WO2000040615A3 (en) 2000-11-23
CZ20012406A3 (cs) 2002-03-13
SK9432001A3 (en) 2003-02-04
EP1141013A2 (en) 2001-10-10
US20040053366A1 (en) 2004-03-18
ZA200105352B (en) 2002-06-28
MXPA01006922A (es) 2002-04-24
KR20020007287A (ko) 2002-01-26
CA2356401A1 (en) 2000-07-13
CN1341121A (zh) 2002-03-20
HUP0105090A2 (hu) 2002-04-29
NO20013371L (no) 2001-09-04
AU2602500A (en) 2000-07-24
JP2002534962A (ja) 2002-10-22

Similar Documents

Publication Publication Date Title
ID30327A (id) EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc
HUP0201474A3 (en) Expression and export of interferon-alpha proteins as fc fusion proteins
NO20016243D0 (no) Anti-alfav-beta3-rekombinante humane antistoffer, nukleinsyrer som koder for de samme og fremgangsmåter foranvendelse
WO1999002711A3 (en) Fusion proteins with an immunoglobulin hinge region linker
ATE458494T1 (de) Von der telomerase abgeleitete antigene peptide
AU2002361642A1 (en) Recombinant antibody fusion proteins and methods for detection of apoptotic cells
AU2002321931A1 (en) Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
DE69703813T2 (de) System zur expression von heterologen antigenen als fusionsproteine
DE50012863D1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
IL158126A0 (en) Peptides and antibodies to muc 1 proteins
NO991340L (no) Stamme-seleksjon av pneumococcale overflateproteiner, beslektede anvendelser
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
NO20042173L (no) Fremgangsmate for fremstilling av rekombinant polypeptid
AU2002235884A1 (en) Method for the identification of extracellular domains of the epstein barr virus (ebv), tumor-associated latent membrane proteins and for the selection of antibody reagents reactive therewith
EP1523492A4 (en) FUSION PROTEIN IGG FC / HIV-GP120 / C3D
DE69938579D1 (de) Extrazelluläre Matrixproteine mit modifizierten Aminosäuren
DE69706505D1 (de) Schmelzkleberzusammensetzung und modifiziertes petroleumharz dafür
IL157264A0 (en) Platelet glycoprotein ib alpha fusion polypeptides and methods of use thereof
AU2002251999A1 (en) Methods and compositions for the construction and use of fusion libraries using computational protein design methods
NO20021275D0 (no) Transgent produserte fusjonsproteiner
ID26730A (id) Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein
DE69823225D1 (de) Fusionsproteine, bestehend aus proteinaseinhibitoren
FI953422A0 (fi) Autolysoivia fuusioproteiineja hyväksikäyttävät ilmentämisjärjestelmät ja uusi pelkistävä polypeptidi
NO20005547D0 (no) Myelinbasiske proteinpeptider og anvendelser derav
NO992531D0 (no) FremgangsmÕter ved fremstilling av rekombinant protein